Challenges in the management of invasive aspergillosis in hematopoietic stem cell transplantation

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 10, 2009, Pages 1151-1153

  Chandrasekar, P H ^a   Ramesh, Mayur ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; TRIAZOLE; VORICONAZOLE;

ASPERGILLOSIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG CHOICE; EARLY DIAGNOSIS; EDITORIAL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; INVASIVE CANDIDIASIS; LIVER FUNCTION TEST; MUCORMYCOSIS; MYCOSIS; SEROLOGY; SIDE EFFECT; TISSUE CULTURE;

ASPERGILLOSIS; CHEMOPREVENTION; GUIDELINES AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; POSTOPERATIVE COMPLICATIONS;

EID: 74249108261     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.105     Document Type: Editorial

References (20)

1. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections m a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 175, 1459-1466 (1997).
2. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter Prospective Antifungal Therapy (PATH) Alliance Registry. Clin. Infect. Dis. 48, 265-273 (2009).
3. Morgan J, Alexander B, Wannemuehler K et al. Quantification of risk for invasive fungal infections (IFI) among transplant (TX) recipients reporting to TRANSNET. Presented at: 44th Interscience Conference on Antimicrobial Agents & Chemotherapy. Washington, DC, USA, 30 October-2 November 2004 (Abstract M-1058).
4. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation. Outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44, 531-534 (2007).
5. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis. 47, 503-509 (2008).
6. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49, 3640-3645 (2005).
7. von Eiff M, Roos N, Schulten R, Hesse M, Zühlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 62, 341-347 (1995).
8. Greene RE, schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin. Infect. Dis. 44, 373-379 (2007).
9. Erjavec Z, Verweij PE. Recent progress in the diagnosis of fungal infections in the immunocompromised host. Drug Resist. Update 5, 3-10 (2002).
10. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 42, 1417-1427 (2006).
11. Meersseman W, Lagrou K, Maertens J et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am. J. Respir. Crit. Care Med. 177, 27-34 (2008).
12. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335-347 (2007).
13. Wingard JR, Carter SL, Walsh TJ et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 110 (2007) (Abstract 163).
14. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect. Dis. 15, 1068-1076 (2009).
15. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39, 425-429 (2007).
16. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin. Microbiol. Infect. 15(Suppl. 5), 93-97 (2009).
17. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring:established and emerging indications. Antimicrob. Agents Chemother. 53, 24-34 (2009).
18. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomographybased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis. 41, 1242-1250 (2005).
19. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis. 48, 1042-1051 (2009).
20. Herbrecht R, Denning DW, Patterson TF et al. Invasive Fungal Infections Group Of The European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415 (2002).